Filing Details

Accession Number:
0001209191-21-055203
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-08 18:20:38
Reporting Period:
2021-09-03
Accepted Time:
2021-09-08 18:20:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1789972 Cullinan Oncology Inc. CGEM () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1687078 Bioimpact Capital Llc C/O Mpm Asset Management Llc
450 Kendall Street
Cambridge MA 02142
No No Yes No
1691428 L.p. Fund Impact Oncology Ubs C/O Mpm Asset Management Llc
450 Kendall Street
Cambridge MA 02142
No No Yes No
1721036 L.p. Management (Cayman) Fund Impact Oncology C/O Mpm Asset Management Llc
450 Kendall Street
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-09-03 12,731 $29.60 7,724,085 No 4 S Direct
Common Stock Disposition 2021-09-07 25,067 $29.04 7,699,018 No 4 S Direct
Common Stock Disposition 2021-09-08 10,842 $29.11 7,688,176 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.
  4. Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.185 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.